Vivos Therapeutics Inc., founded with a mission to revolutionize the treatment of sleep disordered breathing, focuses on innovative medical technologies, particularly for obstructive sleep apnea (OSA). The company offers the Vivos Method, which includes FDA-cleared oral medical devices designed to treat mild, moderate, and severe OSA in adults. Their holistic approach often integrates positive airway pressure (PAP) and myofunctional therapy to enhance patient outcomes. Vivos Therapeutics targets a global market of individuals suffering from sleep-related breathing disorders.

Notable figures affiliated with Vivos Therapeutics include key medical professionals and investors who support its groundbreaking work in sleep medicine. The company has achieved significant milestones, such as receiving the first-ever FDA clearance for an oral device to treat severe OSA. With thousands of patients worldwide benefiting from their treatments, Vivos Therapeutics has made a substantial impact on improving sleep quality and overall health, positioning itself as a leader in the MedTech industry focused on sleep disordered breathing.